NCT00680992 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 268
- group Id
- BG001
- value
- 252
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 532
- units
- Participants
- groups
- description
- Participants with surgically unsalvageable disease (eg, sacral, spinal GCTB, or multiple lesions including pulmonary metastases) were enrolled into cohort 1 and received denosumab 120 mg SC once Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.
- id
- BG000
- title
- Cohort 1 (Denosumab 120 mg Q4W)
- description
- Participants with surgically salvageable disease whose planned initial on-study surgery was associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy) were enrolled into cohort 2 and received denosumab 120 mg SC Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.
- id
- BG001
- title
- Cohort 2 (Denosumab 120 mg Q4W)
- description
- Participants who participated in study 20040215 and were eligible to enroll in the current study (20062004) for continuation of treatment were enrolled into cohort 3 and received denosumab 120 mg SC Q4W, starting on study day 1. Participants in cohort 3 did not receive loading doses of denosumab on days 8 and 15 in the first month of treatment.
- id
- BG002
- title
- Cohort 3 (Denosumab 120 mg Q4W)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 28
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 238
- group Id
- BG001
- value
- 231
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 481
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 23
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 14.6
- value
- 36.4
- group Id
- BG001
- spread
- 13.5
- value
- 35.1
- group Id
- BG002
- spread
- 14.9
- value
- 36.1
- group Id
- BG003
- spread
- 14.1
- value
- 35.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 142
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 301
- title
- Female
- measurements
- group Id
- BG000
- value
- 114
- group Id
- BG001
- value
- 110
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 231
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 221
- group Id
- BG001
- value
- 208
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 440
- title
- White or Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 30
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 27
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 25
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 167
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 167
- title
- Primary resectable
- categories
- measurements
- group Id
- BG000
- value
- 93
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 95
- title
- Primary unresectable
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 85
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 85
- title
- Recurrent resectable
- categories
- measurements
- group Id
- BG000
- value
- 175
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 185
- title
- Recurrent unresectable
- param Type
- NUMBER
- title
- GCTB Disease Type
- unit Of Measure
- Participants
- population Description
- The overall baseline population consisted of the 532 participants enrolled into the treatment phase of the study.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 268
- group Id
- BG001
- value
- 252
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 532
- units
- Participants
- groups
- description
- Participants with surgically unsalvageable disease (eg, sacral, spinal GCTB, or multiple lesions including pulmonary metastases) were enrolled into cohort 1 and received denosumab 120 mg SC once Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.
- id
- BG000
- title
- Cohort 1 (Denosumab 120 mg Q4W)
- description
- Participants with surgically salvageable disease whose planned initial on-study surgery was associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy) were enrolled into cohort 2 and received denosumab 120 mg SC Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.
- id
- BG001
- title
- Cohort 2 (Denosumab 120 mg Q4W)
- description
- Participants who participated in study 20040215 and were eligible to enroll in the current study (20062004) for continuation of treatment were enrolled into cohort 3 and received denosumab 120 mg SC Q4W, starting on study day 1. Participants in cohort 3 did not receive loading doses of denosumab on days 8 and 15 in the first month of treatment.
- id
- BG002
- title
- Cohort 3 (Denosumab 120 mg Q4W)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 28
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 238
- group Id
- BG001
- value
- 231
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 481
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 23
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 14.6
- value
- 36.4
- group Id
- BG001
- spread
- 13.5
- value
- 35.1
- group Id
- BG002
- spread
- 14.9
- value
- 36.1
- group Id
- BG003
- spread
- 14.1
- value
- 35.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 154
- group Id
- BG001
- value
- 142
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 301
- title
- Female
- measurements
- group Id
- BG000
- value
- 114
- group Id
- BG001
- value
- 110
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 231
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 221
- group Id
- BG001
- value
- 208
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 440
- title
- White or Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 30
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 27
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 25
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 167
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 167
- title
- Primary resectable
- categories
- measurements
- group Id
- BG000
- value
- 93
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 95
- title
- Primary unresectable
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 85
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 85
- title
- Recurrent resectable
- categories
- measurements
- group Id
- BG000
- value
- 175
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 185
- title
- Recurrent unresectable
- param Type
- NUMBER
- title
- GCTB Disease Type
- unit Of Measure
- Participants
- population Description
- The overall baseline population consisted of the 532 participants enrolled into the treatment phase of the study.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle